Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Etanercept (Atc Code According to Who: L04ab01)

Completion of a Non-Excl. Discount Agreement According to § 130C Paragraph 1 Sgb V for Mepolizumab Atc Code: R03dx09 for the Period from 03/01/2023 to 02/28/2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Naloxegol, Atc Code: A06ah03 for the Period from 03/01/2023 to 02/28/2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Fentanyl Dihydrogen Citrate, Atc Code: N02ab03 for the Period from 03/01/2023 to 02/28/2025

Drugs Containing the Active Substance Dasatinib (Atc: L01ea02)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Dasatinib (L01ea02) as Part of an Open House Model.

Open House Original Discount Contracts 2023-09 - Hydroxycarbamide (Dosage Form: Film-Coated Tablets, Oral Solution)

Completion of Non-exclusive Drug Discounts According to § 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Everolimus (atc L01eg02)

Completion of Non-exclusive Drug Discounts According to § 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Etanercept (atc Code According to Who: L04ab01)

Open House Discount Contracts 2023-01